| | Welcome to the BRAND NEW Stock Dork Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks. Keep an eye out for our Premarket Reports moving forward and, as always, we invite you to reply to this email with your feedback, suggestions, or comments. Today is Wednesday, May 4th. Let's get ready to trade! |
The S&P 500 gained 0.5% on Tuesday as US markets posted modest gains on the trading session. The Dow and Nasdaq both added 0.2%, and the small-cap Russell 2K jumped 0.9%. Today, futures are up heading into the trading session. Dow and S&P 500 futures are both showing a 0.4% gain in early morning trading. Moderna [MRNA] - Last Close: $146.54 Moderna is trending on the heels of strong earnings numbers. The biotech firm reported Q1 earnings of $8.58 per diluted share on revenues of $6.07 billion, beating the consensus forecast of $5.21 EPS on $4.43 billion in revenues. Moderna's Q1 numbers showed substantial improvements of last year's Q1 figures of $2.84 EPS on revenues of $1.94 billion, MRNA is leading the S&P 500 with a 6.3% gain on active volume. Livent Corp [LTHM] - Last Close: $21.92
Livent Corp is making a big move on news of an upbeat quarter. The lithium stock released its Q1 results after Tuesday's closing bell, and the earnings report is getting a warm reception in today's premarket. Livent generated diluted net earnings of $0.28 per share on revenues of $143.5 million, beating the Street's view of $0.14 EPS on sales of $140.1 million. Livent's also hiked its full-year 2022 revenue forecast to $755 million to $835 million, beating analysts' expectations of $575.6 million, and shares are surging on the heels of the strong report. LTHM is trading actively with a 21.8% premarket gain. Immutep Ltd [IMMP] - Last Close: $2.40
Immutep is surging on a new clinical update. The biotech company reported new biomarker and exploratory analysis data from its PhaseIIb AIPAC trial evaluating efti in combination with paclitaxel chemotherapy. According to company executives, the biomarker analysis confirms efti is activating patients' immune systems and helping patients live longer, and the study noted early rises in ALC in efti-treated patients that could prove to be a potential predictor of improved survival. The upbeat drug data is powering IMMP to a 19.6% gain in today's premarket. Brickell Biotech [BBI] - Last Close: $0.2325 News of an asset sale is rallying shares of Brickell Biotech. The company announced today that it has agreed to sell the rights to sofpironium bromide, a treatment for hyperhidrosis, to Australia-based Botanix Pharmaceuticals Ltd. In exchange, Brickell will receive upfront and potential milestone payments over the next 18 months of up to $9 million. Brickell can also receive additional milestone payments of up to $168 million, with tiered payments ranging from high-0single digits to mid-teen digits on net sales of sofpironium bromide gel. BBI is this morning's most actively traded stock, and it's showing a 23.7% gain. |
Gainers -
Rail Vision Unit [RVSN] >> +38.5% -
Aclarion [ACON] >> +20.4% -
Sharps Technology [STSS] >> +10.2%
Decliners - Lyft Inc [LYFT] >> (25.0%)
- IONQ Inc [IONQ] >> (10.9%)
- Connect Biopharma [CNTB] >> (30.9%)
- CVS Health Corp. [CVS] ... AM
- Regeneron Pharmaceuticals [REGN] ... AM
- Marriott International [MAR] ... AM
- Moderna [MRNA] ... AM
- Barrick Gold [GOLD] ... AM
- Yum! Brands [YUM] ... AM
- eBay [EBAY] ... PM
- Booking Holdings [BKNG] ... PM
- Uber Technologies [UBER] ... PM
- MetLife [MET] ... PM
|
- ADP Employment Report [Apr] ... 8:15a
- Intl. Trade Balance [Mar] ... 8:30a
- ISM Services Index [Apr] ... 10a
- FOMC Statement ... 2p
- Fed Chair Jerome Powell News Conference ... 2:30p
|
Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and I'll get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Dork" Taylor P.S. Want My Alerts Delivered To Your Cell Phone? Sign up for mobile alerts and get the latest updates delivered to your cell. Disclaimer © 2022 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
